Namalva, a human B cell lymphoma line, produced a factor with a molecular weight of -60,000 which enhanced the proliferation of normal activated human B lymphocytes. The factor also enhanced the proliferation of certain B cell lines. It can be distinguished physiologically and biochemically from other lymphokines known to enhance B cell proliferation, namely, interleukin (IL) 1, IL 2, and interferon. The production of B cell growth factor by B cell tumor lines may contribute to their ability to grow autonomously and may reflect an important component of the neoplastic potential of the cell. B cell growth factor produced by tumors may also affect normal cells in vivo.
Introduction
Regulation of the immune response is dependent upon the complex interactions of lymphocyte and monocyte subsets and a variety of cell-derived soluble factors. It has been clearly demonstrated that T lymphocytes produce lymphokines that cause activated B lymphocytes to proliferate: this factor has been termed B cell growth factor (BCGF)' (1) . Furthermore, distinct lymphokines act on the proliferating B cells to induce them to differentiate (2) . The source of BCGF in human studies has been claimed to be one of the following: mitogenstimulated unfractionated peripheral lymphocytes, T cell clones (3), or T-T hybridomas (4) . Long-term growth of nonmalignant and non-Epstein-Barr virus (EBV)-transformed B lymphocytes has been claimed to be dependent upon BCGF (5). Blazar et al. (6) and Gordon et al. (7) have described autostimulatory activity produced by EBV-transformed B cell lines. Gordon et al. .(8) also demonstrated the ability of the EBV-transformed B cell line supernatants to stimulate the proliferation of normal tonsillar B cells, although they did not fully characterize biochemically the substance responsible for this BCGF-like activity and did not distinguish it from other lymphokines such as interferon, interleukin (IL) 1, and IL 2. To our knowledge, the production of BCGF, distinct from other known lymphokines, by human B cell lines capable of acting on normal cells has not been demonstrated. The diffuse immunologic abnormalities associated with leukemias and lymphomas may be due to the production of lymphokines by the tumors that can act on normal cells.
In our study, we demonstrate the physiologic and partial biochemical characteristics of BCGF produced by Namalva, a human Burkitt's lymphoma line, upon stimulation with phytohemagglutinin (PHA). We further demonstrate that certain other B cell lines constitutively produce factors with BCGFlike activity.
Methods
Cell lines. The cell line Namalva has been maintained in our laboratory for several years. B cell lines BALM-1, BALM-4, and BALL-1, and T cell lines Molt-4 and T-ALL were kindly provided by Dr. Jun Minowada, Loyola University, Chicago, IL. Ball-lS and Ball-1A5 are subclones of BALL-l produced by plating BALL-1 at 1 cell/well. After 3 wk, positive wells were screened for responsiveness to BCGF. Ball-IA5 showed increased [3H]thymidine incorporation in response to BCGF while Ball-lS showed decreased [3H]thymidine incorporation in response to BCGF. Ball-1A5 was then maintained in medium containing 10% vol/vol BCGF. 3B3, a human T-T hybridoma, which was developed in our laboratory, produces BCGF in the absence of IL 2 or B cell differentiation factor (BCDF) activity (4) . The characteristics of a BCGF produced by a subclone of 3B3, 2B,1, have been previously reported (9) .
Media. Cell lines were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS; Dutchland Laboratories, Inc., Denver, PA), penicillin (100 ug/ml), streptomycin (100 ,g/ml), and amphotericin (2 gg/ml) (Fungizone; Flow Laboratories, Inc., McLean, VA). Cell lines used for factor production were adapted to growth in complete HB102 (HANA Media, Inc., Berkeley, CA) without FCS.
Reagents. Anti-M is the F(ab')2 fragment of goat antihuman heavy chain-specific IgM (Cappel Laboratories, Cochranville, PA). Staphylococcus aureus Cowan I (SAC) was prepared in our laboratory as previously described (10 1% FCS for 60 min at 370C. Small and large populations of B cells were separated from the B cell-enriched population by counterflow centrifugation-elutriation as previously described (12) .
Preparation offactors. Cell lines were grown at a concentration of 1 X 106 cells/ml. Mitogen stimulation consisted of the addition of 1 jug/ml PHA, 10 Ag/ml Con A, 5 ng/ml PMA, or 10,gg/ml LPS Other lymphokine assays. The IL 1 assay was kindly performed by Dr. Theresa Gerrard as previously described (13). The interferon assay was performed by Biofluids, Inc. (Rockville, MD) as described (14) .
Assessment of B cell differentiation activity of factors was assessed on SAC-activated B cells as discussed (10) . The IL 2 assay was performed as previously described (15) using the IL 2-dependent T cell line HT-2 (kindly provided by Dr. David Volkman, National Institutes of Health). Gelfiltration. Supernatant from Namalva cells (1,000 ml) that had been stimulated with PHA was concentrated to 4 ml by filtration using a YM1O membrane (Amicon Corp. Scientific Sys. Div., Danvers, MA).
Half of the concentrated supernatant was applied to a Sephadex G-100 gel filtration column (90 X 2 cm; Pharmacia Fine Chemicals). The other half of the concentrated supernatant was treated with 5 U/ ml of neuraminidase for 12 h at 37°C before being applied to the column. The column was eluted with phosphate-buffered saline (HEM Laboratories, Rockville, MD) at a flow rate of 10 ml/h; 3.0-ml fractions were collected.
Isoelectric focusing. Isoelectric focusing was performed in a 20 X 11 x 0.5 cm preparative focusing bed (Bio-Rad Laboratories, Richmond, CA) using Pevikon (Accurate Chemical & Scientific Corp., Westbury, NY). Briefly, 112 g of Pevikon was washed three times in distilled water and then allowed to dry. The Pevikon was then saturated with 52 ml of a 1:10 solution of 3.5-10 ampholytes (LKB, Instruments, Inc., Gaithersburg, MD) in distilled water and placed in the focusing bed. Active fractions of the supernatant from PHA-stimulated Namalva, obtained from the G-100 column, were applied in the middle of the focusing bed. This was done separately for neuraminidase-treated and -untreated Namalva supernatant. An electrical current was applied across the bed at a constant power of 5 W. Focusing was completed when 1,000 V were attained. The bed was then sliced and individual sections placed in 10 ml of distilled water and refrigerated at 4°C overnight. The pH of each section was measured and the samples were spun down at 600 g for 30 min. The supernatants were pipetted off and dialyzed against RPMI 1640 for 48 h at 4°C. Individual samples were concentrated by filtration using a PM5 membrane (Amicon Corp. Scientific Sys. Div.) to a total volume of 1 ml. These fractions were then assayed for BCGF activity.
Isoelectric focusing of I'25-labeled purified Namalva factor was done in a 6% acrylamide gel with 0.05% ampholytes. The sample was applied with a 0.5 X 2 cm wick resting on the gel. A current was applied across the gel at a constant power of 5 W. Focusing was completed when 800 V was attained. The gel was then sliced and the 1125 retained in each slice was assessed with a gamma counter. 1 ml distilled water was added to each fraction. 2 h later, the pH of each fraction was measured.
Purification of Namalva (factor). Purification of Namalva (factor) was accomplished by starting with 5 liters of PHA-stimulated Namalva supernatant grown for 72 h in RPMI without added protein. The supernatant was concentrated 100-fold by Amicon filtration using a YM10 membrane. The concentrated factor was then subjected to ion exchange chromatography using DEAE-Sepharose (Pharmacia Fine Chemicals) and a salt gradient of 5-300 mM. Active fractions were subjected to G-100 sieving and then isoelectric focusing as described above. Active fractions from isoelectric focusing were pooled and labeled with 1125 using Bolton-Hunter reagent by a standard procedure (16) .
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.
I'25-labeled Namalva (factor) was analyzed by electrophoresis on a 10%
polyacrylamide gel in 1% SDS (17) . Molecular weight standards (BioRad) were run simultaneously. The gel was then dried and molecular weight markers labeled with an autoradiography marker (Ultemit; New England Nuclear). Autoradiography of the entire gel was then performed.
Results
Characteristics of cell lines. The cell surface staining characteristics of the cell line were examined using an FACS (Table  I) . Namalva was indeed found to be a B cell line as it expressed Namalva (factor) could also enhance the proliferation of certain B cell lines (Table V) . This was best demonstrated on BALL-lA5, a clone of BALL-1. BALL-lA5, selected for its ability to respond to BCGF, was grown in an exogenous source of BCGF. BALM-1, an EBV-positive B cell line with normally slow proliferation, did enhance its proliferation somewhat in the presence of Namalva (factor). Namalva (factor) generally had no effect or a slightly suppressive effect on the proliferation of Namalva cells, perhaps because Namalva was already responding to the factor it had produced. Furthermore, PHA present in Namalva (factor) had a slightly suppressive effect on the proliferation of Namalva cells. Since BCGF-like activity has been variably attributed to IL 1 (19), IL 2 (acting on contaminating T cells to produce BCGF) (20), and interferon (21), attempts were made to distinguish Namalva (factor) from these lymphokines. No IL 1 activity was detected in Namalva (factor) 'using a mouse thymocyte assay (13). IL 2 activity was evaluated by assessing the effect of Namalva (factor) on the proliferation of an IL 2-dependent cell line, HT-2; no activity was found. No interferon activity was detected in Namalva (factor) as determined by its ability to inhibit the proliferation of vesicular stomatitis virus in human amnion cells (14) . Finally, BCDF activity of Namalva (factor) was assessed by measuring the production of Ig by SAC-activated B cells in the presence or absence of Namalva (factor). No enhancement of Ig production was noted in the presence of Namalva (factor) (data not shown). Crude biochemical characterization of Namalva (factor) revealed that it is trypsin sensitive, has a molecular weight of -60,0Q0, and has'isoelectric points of 6.7 and 7.8. Molecular weight determination was made using a G-100 column. Fig. I shows that untreated Namalva (factor) had a high molecular weight activity peak (above the resolving capacity of the column, which is' 100,000 mol wt) along with an additional activity peak of -60,000 mol wt. When concentrated Namalva (factor) was treated with neuraminidase, only the 60,000-molwt activity peak remained. This finding suggests that the protein Namalva (factor) is heavily glycosylated and sialic acid residues may be important in the activity of the high molecular weight peak. Glycosylation of the BCGF may decrease the ability of the G-100 column to sieve it, perhaps by altering its tertiary structure. If, however, aggregation of the factor is Figure 1 . G-100 column of Namalva (factor) before and after neuraminidase treatment. Namalva (factor) was concentrated 100 times and than run over the g-100 column. Fractions were collected and assayed for BCGF activity (-e wusing the anti-g costimulatory assay and absorbance at 280 nm --).Molecular weight standards are shown above the small arrows; d = mol wt.
responsible for the high molecular weight peak, neuraminidase may be somehow preventing this aggregation. Fig. 2 indicates the peaks of BCGF activity obtained when the active fractions of Namalva (factor) from the 0-100 column ( Fig. 1) were focused in a preparative bed of Pevicon with ampholytes. The isoelectric points, before neuraminidase treatment, are 6.7 and 7.8, similar to the isoelectric points of 3B3-produced BCGF (9) . Neuraminidase-treated Namalva (factor) has two distinct isoelectric points, 7.1 and 7.8. Namalva (factor) purified by ion exchange chromatography, G-100 sieving, and then isoelectric focusing, was iodinated with the Bolton-Hunter reagent. Fig. 3 shows the autoradiography of 'I'y-labeled Namalva (factor) in a 10% SDShpolyacrylamide gel. The molecular weight of iodinated Namalva (f'actor) is =.60,000 without a significant shift in migration of the band after reduction with 2-mercaptoethanol. Fig. 4 shows that this iodinated protein has isoelectric points of 6.1 and 7.6, similar to the isoelectric points of uniodinated Namalva (factor). Furthermore, Figure 2 . Isoelectric focusing of the active fractions from the G-100 column of Namalva (factor) before and after neuraminidase treatment. Active fractions from G-100 sizing were placed in a bed of Pavikon and exposed to an electrical current at a constant power of 5 W until 1,000 V was attained. The bed was sliced, and individual fractions were dialyzed and then assayed for pH and BCGF activity (e) in an anti-M costimulator assay.
certain B cell lines to use this BCGF. These observations are of potential importance because BCGF is a lymphokine that is generally thought of as T cell derived and that modulates B f PHA used at 1 Ag/ml. § Namalva (factor) and I'25-labeled Namalva (factor) were used at 25% vol/vol. 11 From below, 7,228 -2,068 = 5,160. ¶ 20 X of I'25-labeled Namalva (factor) was placed in hydrofluor. Beta counts/I min were measured using a model LS9000 (Beckman Instruments, Inc., Fullerton, CA) set to an energy window of 0-397, then gamma counts/I min were measured using a gamma system (Beckman Instruments, Inc); (23,000/37,627) (3,328) = 2,068.
To our knowledge, no other human B cell line has been demonstrated to produce BCGF. The autostimulatory activity produced by EBV-transformed B cell lines described by Blazar et al. (6) and Gordon et al. (7, 8) was not characterized as a distinct or unique lymphokine. Yoshizaki et al. (23) have demonstrated BCDF activity in a clone of the BCDF-responsive, EBV-transformed line CESS. In the murine system, ClarkLewis et al. have found a B cell line, WEHI-231.1, which produces IL 1, T cell-replacing factor, colony-stimulating factor, and P cell-stimulating factor activity (24) . The supernatant from WEHI-231.1 can enhance the proliferation of mouse B cells (24) . However, IL 1, which is contained in the supernatant, has been demonstrated to enhance the proliferation of anti-Mactivated B cells or to synergize with BCGF to further enhance proliferation (18) .
In these studies, we attempted to distinguish Namalva (factor) from the other lymphokines that are known to be capable of enhancing B cell proliferation. Namalva (factor) failed to demonstrate IL 1 activity in a standard IL 1 assay using mouse thymocytes (12) . Furthermore, it has a molecular weight of -60,000 while IL 1 has a molecular weight of 15,000 (25) . However, IL 1 produced by a murine cell line has been found to have a molecular weight between 50,000 and 89,000 by gel filtration chromatography (26) . Namalva (factor) can be distinguished from IL 2 by physiologic as well as biochemical criteria. It failed to sustain the proliferation of HT-2. In addition, it has a much higher molecular weight (-60,000 vs. 15,500) than IL 2 (27) and a more alkaline isoelectric point (6.7-7.8 vs. 3.5-4.5) (28) .
The possibility that Namalva (factor) may be an interferon was a major concern since interferon can enhance the proliferation of SAC-activated B cells (20). However, no antiviral activity could be demonstrated by the factor on human amniotic cells. Biochemically, Namalva (factor) cannot be distinguished from all interferons because of the wide range in their reported molecular weights and isoelectric points (29) . However, it is clear that Namalva (factor) described here is biochemically different from the 1 8,000-mol-wt interferon produced by Namalva infected with Sendai virus (30) . Finally, Pickering et al. (30) confirm our finding that uninfected Namalva fails to produce any interferon. Namalva (factor) appears to be a BCGF or BCGFs, although it is not entirely clear whether it is a physiologically important lymphokine or merely a cellular byproduct of an EBV-transformed malignant cell line. EBV particles have been shown to range from a molecular weight of 290,000 to 28,000 (31) . While there is no absolute way of determining its importance, several lines of evidence argue against Namalva (factor) being a trivial byproduct of EBV. First, Namalva contains very little EBV DNA and does not secrete EBV particles (G. Armstrong, personal communication). Second, several known EBV-transformed cell lines such as BALM-I and NALM-6 do not generate BCGF-like activity after mitogen stimulation. Finally, BALL-I has been successfully cloned with the result that some clones (Ball-IS) produced large amounts of BCGF-like activity while others (Ball-1A5) produced no BCGF activity but enhanced their proliferation in response to Namalva (factor) or other types of human BCGF (Table V) Physiologically, Namalva (factor) enhanced the proliferation of large, presumably activated B lymphoytes (12) more than small resting B lymphocytes costimulated with antijs. It, however, can clearly act on both of these B cell populations. It was found to be similar to the BCGF produced by T-ALL both physiologically and biochemically (data not shown) but different from the BCGF produced by 3B3 both physiologically (acting preferentially on large rather than small costimulated B cells) and biochemically (Namalva [factor] molecular weight 60,000 vs. that of 3B3, -20,000). Namalva (factor) is somewhat analogous to the late acting BCGF II described in the murine system by Swain et al. (32) and in the human system by Okada et al. (33) .
Large quantities of Namalva (factor) must be purified to determine its exact biochemical characteristics so that it may be compared with other known lymphokines. Purification will also allow further exploration of the physiologic effects of the factor on various B cell populations and of the interaction of this factor with other BCGF. Ultimately, with the purification of the factor and the receptor(s) with which it interacts, we will be able to determine if normal B cells can produce the same factor and to see the conditions under which normal and malignant B cells produce the factor.
